Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Department of Family Medicine, Changhua Christian Hospital, Changhua, Taiwan.
Front Immunol. 2021 Oct 12;12:729501. doi: 10.3389/fimmu.2021.729501. eCollection 2021.
Atopic march refers to the natural history of atopic dermatitis (AD) in infancy followed by subsequent allergic rhinitis and asthma in later life. Respiratory viruses interact with allergic sensitization to promote recurrent wheezing and the development of asthma. We aimed to evaluate whether influenza vaccination reduces asthma risk in people with AD.
This cohort study was conducted retrospectively from 2000 to 2013 by the National Health Insurance Research Database (NHIRD). Patients with newly diagnosed AD (International Classification of Diseases, Ninth Revision, Clinical Modification code 691) were enrolled as the AD cohort. We matched each vaccinated patient with one non-vaccinated patient according to age and sex. We observed each participant until their first asthma event, or the end of the study on December 31, 2013, whichever came first.
Our analyses included 4,414 people with a mean age of 53 years. Of these, 43.8 were male. The incidence density of asthma was 12.6 per 1,000 person-years for vaccinated patients, and 15.1 per 1000 person-years for non-vaccinated patients. The adjusted hazard ratio (aHR) of asthma in the vaccinated cohort relative to the non-vaccinated cohort was 0.69 (95% CI = 0.55-0.87). Vaccinated patients had a lower cumulative incidence of asthma than unvaccinated patients. Vaccinated participants in all age and sex groups trended toward a lower risk of asthma. People will reduce more asthma risk when taking shots every year.
Influenza vaccination was associated with lower asthma risk in patients with AD.
特应性进行曲是指婴儿期特应性皮炎(AD)随后在以后的生活中出现过敏性鼻炎和哮喘的自然病史。呼吸道病毒与过敏致敏相互作用,促进反复喘息和哮喘的发展。我们旨在评估流感疫苗接种是否可以降低 AD 患者的哮喘风险。
这项队列研究是通过国家健康保险研究数据库(NHIRD)在 2000 年至 2013 年期间进行的回顾性研究。将新诊断为 AD(国际疾病分类,第九修订版,临床修正版代码 691)的患者纳入 AD 队列。我们根据年龄和性别为每个接种疫苗的患者匹配一个未接种疫苗的患者。我们观察每个参与者,直到他们首次发生哮喘事件,或 2013 年 12 月 31 日研究结束,以先发生者为准。
我们的分析包括 4414 名平均年龄为 53 岁的患者。其中,男性占 43.8%。接种患者的哮喘发病率密度为每 1000 人年 12.6 例,未接种患者为每 1000 人年 15.1 例。与未接种组相比,接种组哮喘的调整后危险比(aHR)为 0.69(95%CI=0.55-0.87)。接种组的累积哮喘发生率低于未接种组。在所有年龄和性别组中,接种组的哮喘风险均呈下降趋势。每年接种疫苗的人将降低更多的哮喘风险。
流感疫苗接种与 AD 患者的哮喘风险降低相关。